Medication info

Olmesartan Medoxomil and Amlodipine Tablets 5/40 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.944mg / 1 tablet
Manufacturer / importer
Pharmagen Science Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
28 tablets/box [14 tablets/PTP × 2]
Approval status
Expired

MFDS item code 202002849 · Approved 2020.04.22

This product's status changed to Expired on 2025.04.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with careful monitoring of their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
Pharmagen Science Co., Ltd.

Efficacy & effects

Treatment of essential hypertension not controlled with monotherapy

  • Essential hypertension
View approved original text

Amlodipine and Olmesartan Medoxomil are used for patients with essential hypertension, which occurs without a known cause. Both medications effectively lower blood pressure, helping when blood pressure is not adequately controlled. These drugs reduce burden on the heart and blood vessels, contributing to the prevention of complications. If blood pressure cannot be controlled with monotherapy, other treatment methods may also be used in combination. These medications play a significant role in managing hypertension and contribute to improving health. Therefore, they are used for the treatment of essential hypertension.

How to take

Adult dose

This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended that treatment be initiated at a low dose with careful monitoring of their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, take the patient's renal or cardiac function and comorbidities into consideration. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Individuals who are allergic to this medication's active ingredients or similar components, who are pregnant or breastfeeding, those with severe liver dysfunction, severe aortic valve stenosis, bile duct obstruction, patients undergoing dialysis, those in a state of shock, and specific diabetes patients should not take this medication. Patients with low blood pressure or those with conditions that cause blood vessels to dilate, patients with severe obstructive coronary artery disease, congestive heart failure, impaired kidney function, and those with liver dysfunction should use this medication cautiously and consult healthcare professionals immediately if symptoms of low blood pressure or other side effects occur. This medication can cause various side effects such as dizziness, headache, low blood pressure, orthostatic hypotension, heart palpitations, dyspepsia, nausea, skin rash, and edema, so any abnormal symptoms should be reported to healthcare providers. The use of this medication is prohibited during pregnancy due to the risk of fetal damage, and it should be replaced with safer alternatives if planning to conceive or if pregnancy is suspected. If breastfeeding, it is recommended to discontinue either breastfeeding or the medication, as this drug can be transmitted through breast milk and may affect the infant. It is advised not to use in children under 18 years, as safety and efficacy have not been established for this group. Elderly patients should start with a low dose due to the potential for increased drug concentrations in the body from decreased kidney and liver function and should adjust the dose cautiously. In case of overdose, symptoms of low blood pressure and reduced heart function may arise; appropriate treatment must be sought immediately. Avoid taking this medication with grapefruit juice, as it may excessively enhance the blood pressure-lowering effect, and consult healthcare providers regarding potential interactions when taking with other medications. Store this medication in a place out of reach of children, keeping it away from moisture, heat, and direct sunlight.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • reduced sensation
  • syncope
Show 75 more
  • vertigo
  • palpitations
  • rapid pulse
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • indigestion
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle stiffness
  • limb pain
  • low back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • weakness
  • facial edema
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • aggravation of cerebral infarction
  • gum bleeding
  • laryngitis
  • arthritis
  • generalized pain
  • chest burning
  • weakness
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • rhabdomyolysis
  • hair loss
  • itching
  • urticaria
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • dizziness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • bradycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, and should be stored in a tightly closed container. It is advisable to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. This helps to preserve the effectiveness of the medication for a longer period.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

28 tablets/box [14 tablets/PTP × 2]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.